A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects

Receptor‐interacting protein kinase 1 (RIPK1) mediates necroptosis and inflammation in various pathophysiologies, emerging as a pharmacological target for neurodegenerative and inflammatory indications. This phase I, first‐in‐human, placebo‐controlled study evaluated the safety, pharmacokinetics (PK...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, Jason, Wang, Shuang, Zhang, Wenxin, Zhu, Huaqiang, Wang, Jing, Zhao, Congqiao, Shen, Haige, Wang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499419/
https://www.ncbi.nlm.nih.gov/pubmed/37345561
http://dx.doi.org/10.1111/cts.13580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499419/
https://www.ncbi.nlm.nih.gov/pubmed/37345561
http://dx.doi.org/10.1111/cts.13580

Ejemplares similares